List of Excipients in Branded Drug ESOMEPRAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dexcel Pharma Technologies Ltd	ESOMEPRAZOLE	esomeprazole	64239-112	ACETONE
Dexcel Pharma Technologies Ltd	ESOMEPRAZOLE	esomeprazole	64239-112	ALCOHOL
Dexcel Pharma Technologies Ltd	ESOMEPRAZOLE	esomeprazole	64239-112	ASCORBIC ACID

Generic Drugs Containing ESOMEPRAZOLE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	esomeprazole	0591-4187	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	esomeprazole	0591-4187	CROSPOVIDONE
Actavis Pharma Inc	esomeprazole	0591-4187	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in ESOMEPRAZOLE?

# Of NDCs	Excipient
1	ACETYLTRIBUTYL CITRATE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE

Esomeprazole Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

Esomeprazole is a mature proton-pump inhibitor with limited molecule-level exclusivity but continuing commercial value in differentiated dosage forms, pediatric delivery, hospital formulations, combination products, and manufacturing platforms. The central formulation problem is acid instability. Commercially viable products typically use enteric protection, multiparticulate delivery, alkaline microenvironments, or parenteral stabilization.

What excipient strategy is required for esomeprazole?

Esomeprazole requires excipients that protect the active ingredient from gastric acid, support reproducible release in the intestine, and maintain chemical stability during manufacturing and storage.

Esomeprazole is the S-isomer of omeprazole. Like other proton-pump inhibitors, it is acid-labile and is generally administered in delayed-release formulations. The formulation strategy must prevent substantial exposure to gastric acid before intestinal release.

Formulation objective	Typical excipient or technology	Commercial purpose
Protect esomeprazole from gastric acid	Methacrylic acid copolymers, commonly enteric polymers	Delayed release in the intestine
Create an alkaline microenvironment	Magnesium oxide, magnesium carbonate, sodium hydroxide, or other alkalizing agents	Improve chemical stability
Build multiparticulate units	Sugar spheres, microcrystalline cellulose, starch, hypromellose	Enable capsule filling and dose flexibility
Control drug-layer adhesion	Hypromellose, povidone, hydroxypropyl cellulose	Improve coating uniformity
Improve coating flexibility	Triethyl citrate, polyethylene glycol, or other plasticizers	Reduce cracking and premature release
Reduce sticking and improve processing	Talc, colloidal silicon dioxide, magnesium stearate	Support manufacturing efficiency
Improve aqueous dispersion	Polysorbates, suspending agents, viscosity modifiers	Support oral suspensions and pediatric products
Stabilize parenteral product	Buffers, alkalizing agents, chelators, tonicity agents	Maintain solution stability after reconstitution

The precise composition varies by manufacturer and dosage form. FDA-approved labels identify inactive ingredients at the product level, but they do not always disclose the complete quantitative formulation.

What formulations are protected by esomeprazole excipients?

The highest-value formulation opportunities are delayed-release capsules, delayed-release tablets, oral suspensions, orally disintegrating products, and injectable products.

Delayed-release capsules

Nexium delayed-release capsules use enteric-coated pellets rather than a conventional immediate-release powder blend. This design provides several commercial advantages:

• Protection of esomeprazole during gastric transit.
• More uniform intestinal release.
• Compatibility with capsule-opening instructions for selected patients.
• Potential use in dose strengths such as 20 mg and 40 mg.
• Ability to manufacture multiple strengths by varying pellet load.

The pellet system usually contains a drug layer applied to inert cores, a protective subcoat, and an enteric coat. The drug layer may include an alkalizing agent to reduce acid-mediated degradation. The enteric coat commonly uses a methacrylic acid copolymer with a plasticizer and anti-tacking agent.

Capsule products create opportunities for excipient suppliers in:

• Enteric polymers.
• Pharmaceutical-grade sugar spheres.
• Plasticizers.
• Coating-process equipment.
• Continuous pellet coating.
• Low-moisture manufacturing systems.

Delayed-release tablets

Delayed-release tablets can use a matrix or core containing esomeprazole, an alkaline stabilizer, and a polymeric enteric coating. Tablets may offer lower packaging costs, easier high-speed production, and stronger brand differentiation than standard capsules.

The technical risk is greater than with multiparticulate capsules. A tablet must maintain acid resistance despite compression forces, coating defects, core porosity, and changes in dissolution during storage. The tablet core may require:

• A low-moisture excipient system.
• Controlled alkalinity.
• A robust protective subcoat.
• A flexible enteric film.
• Tight control of compression hardness and friability.

Tablet products can support intellectual-property claims based on coating sequence, pH-dependent dissolution, excipient ratios, manufacturing conditions, and stability performance.

Oral suspension and pediatric formulations

Esomeprazole oral suspension products create a commercially relevant niche because young children and patients with swallowing difficulties may not tolerate conventional capsules or tablets.

A suspension system must address:

• Uniform dose delivery after shaking.
• Sedimentation and redispersion.
• Preservation.
• Flavor masking.
• Compatibility with enteric-coated granules.
• Stability after reconstitution.
• Administration through feeding tubes.

The most defensible formulation architecture is often a suspension containing delayed-release granules rather than dissolved esomeprazole. Dissolving the active ingredient in an aqueous vehicle can expose it to hydrolysis and create stability problems.

Potential excipient classes include:

• Suspending agents such as xanthan gum or cellulose derivatives.
• Wetting agents.
• Sweeteners and flavors.
• Buffers.
• Preservatives, where permitted and justified.
• Osmolality modifiers.
• Antifoaming agents.

Pediatric products can command higher margins than undifferentiated adult generics when they solve administration and dosing problems that are not addressed by standard capsules.

Orally disintegrating and sprinkle formulations

Orally disintegrating tablets and granule-based sprinkle products may target patients who cannot swallow conventional dosage forms. The product must preserve delayed release even when the dosage form disintegrates in the mouth.

This usually requires enteric-coated granules embedded in a rapidly dispersing tablet or supplied in a sachet. The core challenge is to maintain:

1. Fast oral disintegration.
2. Minimal premature drug release.
3. Acceptable mouthfeel.
4. Stable granule coating.
5. Reliable delivery through soft food or liquid.

Direct compression is possible for some designs, but multiparticulate systems generally provide more control over acid resistance.

Which excipients offer the strongest commercial opportunities?

The most attractive opportunities are not necessarily commodity fillers. Value is concentrated in excipients that improve stability, coating performance, process yield, or patient administration.

Opportunity	Commercial attractiveness	Main technical barrier
Enteric polymers optimized for low-temperature processing	High	Balancing acid resistance with intestinal release
Ready-to-use coating systems	High	Compatibility with esomeprazole alkalinity and moisture sensitivity
Low-moisture alkaline excipient blends	High	Uniformity and long-term stability
Pediatric suspension vehicles	High	Dose uniformity and preservative compatibility
Sprinkle and feeding-tube systems	Medium to high	Granule integrity and tube recovery
Direct-compression tablet platforms	Medium	Premature release and coating defects
Standard fillers and lubricants	Low	Price competition and limited differentiation
Parenteral stabilizers and packaging systems	Medium	Reconstitution stability and hospital workflow

A supplier with a proprietary enteric polymer system can compete on release performance, coating weight, process temperature, and reduced solvent use. A supplier offering a complete formulation package has a stronger commercial position than one selling an undifferentiated excipient.

How does esomeprazole excipient selection affect manufacturing?

Manufacturing performance is a major source of product differentiation after basic patent expiry.

Pellet layering

Pellet manufacture may use fluid-bed coating or rotor processing. Critical variables include:

• Drug-layer uniformity.
• Spray rate.
• Inlet temperature.
• Atomization pressure.
• Pellet moisture.
• Coating weight gain.
• Agglomeration.
• Residual solvent or water.

Esomeprazole may require an alkaline layer or protective subcoat before application of the enteric polymer. Insufficient separation between the drug layer and enteric coat can cause instability or poor dissolution.

Enteric coating

The coating must meet acid-resistance requirements while releasing the drug promptly at intestinal pH. Excessive coating thickness can delay release. Inadequate coating can produce premature release in the stomach.

Commercially important process controls include:

• Film thickness.
• Polymer neutralization.
• Plasticizer level.
• Talc dispersion.
• Spray pattern.
• Bed temperature.
• Drying endpoint.
• Packaging moisture control.

Moisture management

Moisture can affect esomeprazole stability, coating integrity, and dissolution. Manufacturers may use high-barrier blister packaging, desiccants, or tightly controlled bottle systems.

Packaging is therefore part of the excipient and formulation strategy. A chemically stable formulation that requires expensive packaging may be less competitive than a slightly more complex formulation with better moisture tolerance.

What is the FDA regulatory status of esomeprazole?

Esomeprazole has FDA-approved products in oral and intravenous dosage forms. Nexium was approved for delayed-release capsules, delayed-release oral suspension, and intravenous use. Generic esomeprazole products have been approved through the abbreviated new drug application pathway.

Product category	FDA pathway	Regulatory issue
Delayed-release capsule	ANDA or NDA	Bioequivalence and delayed-release performance
Delayed-release tablet	ANDA or NDA, depending on reference product	Dosage-form equivalence and dissolution
Oral suspension	NDA or ANDA where a suitable reference exists	Particle size, redispersibility, stability
Intravenous esomeprazole sodium	NDA or ANDA	Reconstitution, solution stability, sterility
Pediatric sprinkle product	NDA or ANDA depending on reference	Administration with soft food or liquid
Combination product	NDA or ANDA depending on legal basis	Compatibility and contribution of each active

FDA product labeling identifies the inactive ingredients used in individual products. DailyMed is a practical source for comparing marketed formulations, but excipient composition should be verified against the current manufacturer label before regulatory or litigation use (U.S. Food and Drug Administration, n.d.-a; National Library of Medicine, n.d.).

When did esomeprazole lose exclusivity?

The core commercial exclusivity for esomeprazole has expired in the United States. AstraZeneca’s original Nexium patent and regulatory exclusivity strategy protected the product during the 2000s and early 2010s, but generic delayed-release products subsequently entered the market.

The relevant distinction is between:

• Active-ingredient exclusivity.
• Formulation patents.
• Method-of-use patents.
• Pediatric exclusivity.
• Regulatory exclusivity for specific dosage forms.

The expiry of core protection does not eliminate opportunities for narrower formulation patents. A product may still obtain protection for a particular suspension, coating architecture, combination, dosing regimen, or manufacturing method if the claims satisfy patentability and enablement standards.

What patents can still protect esomeprazole products?

Current commercial protection is more likely to arise from formulation and manufacturing claims than from the esomeprazole molecule itself.

Formulation patents

Potential claim categories include:

• Enteric-coated granules with specified dissolution profiles.
• Alkaline stabilizer ratios.
• Specific polymer and plasticizer combinations.
• Moisture-resistant pellet systems.
• Oral suspensions containing delayed-release granules.
• Sprinkle products for administration with food.
• Stable intravenous formulations.
• Specific particle-size distributions.
• Packaging systems that preserve potency.

Method-of-use patents

Method-of-use claims may cover:

• Pediatric dosing.
• Administration through feeding tubes.
• Treatment of specific acid-related disorders.
• Use in combination with antibiotics.
• Dosing schedules for nocturnal acid control.
• Use in patients with particular metabolic or clinical characteristics.

These claims face practical enforcement limitations when the product has broad generic use. Label language, physician prescribing behavior, and the scope of induced-infringement evidence are important.

Manufacturing patents

Manufacturing claims can protect:

• Drug layering on inert cores.
• Low-temperature enteric coating.
• Continuous fluid-bed processing.
• Specific drying conditions.
• Crystallization or salt formation.
• Methods that reduce degradation products.
• Process controls linked to dissolution performance.

Manufacturing patents can be commercially important even when they do not block every generic product. They may limit access to a high-yield process or create licensing value for contract manufacturers.

Are Paragraph IV challenges relevant to esomeprazole?

Paragraph IV litigation was relevant during the initial generic entry period, when applicants challenged listed patents for Nexium delayed-release products. The commercial significance of Paragraph IV disputes is now lower for the base product because multiple generic products are already available.

Future Paragraph IV activity could still arise for:

• New pediatric formulations.
• Orally disintegrating products.
• Modified-release products.
• Combination therapies.
• Long-acting or depot systems.
• Newly approved methods of use.

The Orange Book remains the principal source for listed patents and exclusivity associated with FDA-approved drug products. Patent listings should be reviewed by product strength and dosage form because a patent covering an oral suspension may not cover a conventional delayed-release capsule (U.S. Food and Drug Administration, n.d.-b).

What is the Orange Book status of esomeprazole?

Esomeprazole products have historically been listed in the Orange Book under NDA products such as Nexium. The practical Orange Book analysis requires separating:

• Original Nexium delayed-release capsules.
• Delayed-release oral suspension.
• Intravenous esomeprazole sodium.
• Generic products approved under ANDAs.
• Any later-approved dosage forms.

A listed patent may affect the approval or launch timing of an ANDA, but the commercial effect depends on patent scope, litigation outcome, settlement terms, and whether the applicant uses a noninfringing formulation.

For investment or licensing analysis, the relevant question is not whether esomeprazole has listed patents in the abstract. It is whether the listed claims read on the proposed product and whether the applicant can launch at risk.

Are biosimilar risks relevant to esomeprazole?

No. Esomeprazole is a small-molecule drug, not a biologic. Biosimilar pathways do not apply. Competitive threats arise from:

• Generic delayed-release capsules.
• Generic delayed-release tablets.
• Authorized generics.
• Alternate proton-pump inhibitors.
• H2-receptor antagonists.
• Over-the-counter acid-reduction products.
• Combination products.

The main regulatory pathway is ANDA approval, not an abbreviated biologics license application.

How does esomeprazole compare with competing proton-pump inhibitors?

Product	Active ingredient	Formulation burden	Differentiation opportunity
Nexium and generics	Esomeprazole	High because of acid lability and delayed release	Pediatric, suspension, sprinkle, combination
Prilosec and generics	Omeprazole	High	Established multiparticulate and OTC products
Prevacid and generics	Lansoprazole	High	Orally disintegrating and pediatric formats
Protonix and generics	Pantoprazole	High, especially for IV and delayed release	Hospital and IV applications
AcipHex and generics	Rabeprazole	High	Delayed-release and regional formulations

Esomeprazole benefits from strong physician familiarity and extensive clinical use. It competes in a crowded category where formulation convenience, reimbursement, manufacturing cost, and channel access often matter more than small efficacy differences.

What licensing and commercial opportunities exist for esomeprazole?

The strongest opportunities are platform-oriented rather than molecule-exclusive.

Excipient and technology licensing

Potential licensors include companies with:

• Enteric coating systems.
• Functionalized polymers.
• Multiparticulate processing technology.
• Pediatric suspension platforms.
• Taste-masking technology.
• Feeding-tube delivery systems.
• Moisture-barrier packaging.
• Continuous coating equipment.

A formulation owner may license a complete product package covering composition, process, analytical methods, and regulatory support.

Contract development and manufacturing

CDMOs can compete by offering:

• Pellet development.
• Fluid-bed coating.
• High-throughput capsule filling.
• Sterile intravenous manufacturing.
• Stability programs.
• Scale-up under GMP conditions.
• Regulatory filing support.

For esomeprazole, process capability is often more valuable than access to the active ingredient because the active is widely available from multiple API suppliers.

Combination products

Esomeprazole may be combined with antibiotics for Helicobacter pylori eradication or with other gastrointestinal therapies. Combination products create formulation and regulatory complexity but can improve adherence and reduce direct price comparison.

The principal barriers are:

• Compatibility between actives.
• Different release requirements.
• Dose flexibility.
• Clinical and regulatory evidence.
• Labeling restrictions.
• Intellectual-property clearance.

What generic launch risks exist for new esomeprazole products?

A new entrant faces five principal risks:

1. Bioequivalence risk. Delayed-release products require reliable comparative dissolution and pharmacokinetic performance.
2. Stability risk. Acid-labile drugs can generate degradation during development or commercial storage.
3. Manufacturing risk. Pellet coating and granule uniformity can reduce yield.
4. Regulatory risk. A formulation may not qualify for the intended ANDA pathway if it differs materially from the reference product.
5. Commercial risk. Standard delayed-release capsules face intense price competition.

Differentiated products can reduce price pressure, but they require evidence that the new dosage form solves a meaningful administration, adherence, or hospital-use problem.

Key Takeaways

• Esomeprazole formulation strategy centers on acid protection, alkaline stabilization, and controlled intestinal release.
• Multiparticulate enteric-coated capsules remain the most established commercial architecture.
• Pediatric suspensions, sprinkle products, feeding-tube formats, and orally disintegrating products offer the clearest differentiation opportunities.
• Excipient value is concentrated in enteric polymers, coating systems, alkaline stabilizer blends, suspension platforms, and moisture-control technologies.
• Core esomeprazole exclusivity has expired, and the molecule has no biosimilar risk because it is a small molecule.
• Remaining patent opportunities are concentrated in formulations, methods of use, manufacturing processes, and packaging.
• Generic competition limits the attractiveness of undifferentiated delayed-release capsules.
• Licensing value is strongest for complete formulation and manufacturing platforms rather than commodity excipients.
• Commercial diligence should compare Orange Book listings, current FDA labels, dissolution performance, manufacturing yield, packaging requirements, and product-specific litigation exposure.

FAQs

What is the most important excipient in esomeprazole capsules?

No single excipient determines performance. The enteric polymer system is usually the most important component because it controls gastric resistance and intestinal release. Alkalizing agents and protective subcoats are also critical to chemical stability.

Can esomeprazole be formulated as an immediate-release tablet?

An immediate-release oral tablet is generally unsuitable for conventional systemic esomeprazole delivery because the active ingredient is acid-labile. A viable product would require protection from gastric acid or a different delivery route.

Why are esomeprazole products often manufactured as pellets?

Pellets allow more uniform enteric coating, flexible dose loading, and distribution throughout the gastrointestinal tract. They also support capsule-opening and sprinkle administration for selected products.

Which excipient suppliers are most relevant to esomeprazole development?

Relevant suppliers include manufacturers of pharmaceutical-grade methacrylic acid copolymers, hypromellose, plasticizers, sugar spheres, cellulose-based suspending agents, alkalizing agents, and high-barrier packaging systems. Supplier selection depends on regulatory status, regional availability, and coating-process compatibility.

Does esomeprazole have a strong patent estate today?

The original molecule and core product protection are no longer the principal commercial barriers. Patent strength is more likely to come from narrow formulation, manufacturing, pediatric, combination, or administration claims tied to a specific product design.

References

1. National Library of Medicine. (n.d.). DailyMed: Esomeprazole and Nexium product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2015). Nexium prescribing information. AstraZeneca Pharmaceuticals LP.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.